chr2:96143169:> Detail (hg38)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr2:96,808,908-96,811,179 |
| hg38 | chr2:96,143,169-96,145,440 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| <0.001 | endometriosis | NA | BeFree | Detail | |
| <0.001 | Glioma | NA | BeFree | Detail | |
| <0.001 | hydrocephalus | NA | BeFree | Detail | |
| <0.001 | Congenital hydrocephalus | NA | BeFree | Detail | |
| 0.002 | Inflammation | NA | GAD | Detail | |
| 0.003 | leukemia | NA | LHGDN | Detail | |
| <0.001 | chronic lymphocytic leukemia | B-PAC-1 in combination with an inhibitor of apoptosis protein antagonist (Smac06... | BeFree | 25538042 | Detail |
| 0.002 | Lymphoma, Non-Hodgkin | NA | GAD | Detail | |
| <0.001 | multiple myeloma | Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC... | BeFree | 26257207 | Detail |
| <0.001 | neuroblastoma | NA | BeFree | Detail | |
| <0.001 | oligodendroglioma | NA | BeFree | Detail | |
| <0.001 | ovarian carcinoma | NA | BeFree | Detail | |
| 0.001 | Pituitary Diseases | NA | BeFree | Detail | |
| <0.001 | retinoblastoma | NA | BeFree | Detail | |
| <0.001 | schizophrenia | NA | BeFree | Detail | |
| <0.001 | post-traumatic stress disorder | NA | BeFree | Detail | |
| <0.001 | Stress, Psychological | NA | BeFree | Detail | |
| <0.001 | acute leukemia | NA | BeFree | Detail | |
| <0.001 | Migraine Disorders | NA | BeFree | Detail | |
| <0.001 | Neuroendocrine Tumors | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of lung | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
| <0.001 | prostate carcinoma | NA | BeFree | Detail | |
| <0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
| <0.001 | breast carcinoma | NA | BeFree | Detail | |
| <0.001 | Carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | colon carcinoma | NA | BeFree | Detail | |
| <0.001 | Central neuroblastoma | NA | BeFree | Detail | |
| <0.001 | Well Differentiated Oligodendroglioma | NA | BeFree | Detail | |
| <0.001 | pancreatic ductal adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Mammary Neoplasms | NA | BeFree | Detail | |
| <0.001 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
| <0.001 | Bisphosphonate-associated osteonecrosis | NA | BeFree | Detail | |
| 0.120 | Juvenile arthritis | NA | CTD_human | Detail | |
| <0.001 | Congenital Abnormality | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of colon | DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus G... | BeFree | 23027623 | Detail |
| <0.001 | Rectal Carcinoma | DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus G... | BeFree | 23027623 | Detail |
| <0.001 | colon carcinoma | DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus G... | BeFree | 23027623 | Detail |
| <0.001 | Mental disorders | NA | BeFree | Detail | |
| <0.001 | bipolar disorder | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of breast | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of colon | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of prostate | NA | BeFree | Detail | |
| <0.001 | Rectal Carcinoma | NA | BeFree | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| B-PAC-1 in combination with an inhibitor of apoptosis protein antagonist (Smac066) synergistically i... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112... | DisGeNET | Detail |
| DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112... | DisGeNET | Detail |
| DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs112956 dbSNP
- Genome
- hg38
- Position
- chr2:96,143,169-96,145,440
- Variant Type
- snv
Genome browser